24 completed, 15 recruiting, 14 terminated, 10 active not recruiting. 70 Phase 1, 28 Phase 2.
Follow Folinic acid: new trials by email Literature Review of Folinic acid trials Research Report on Folinic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 35 | 2026-02-16 | 2026-08-19 |
| Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers Capecitabine, Docetaxel, Fluorouracil - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8 | Phase 1 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2025-12-31 | 2025-02-07 | |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) | Phase 1 | Recruiting | Pfizer | 260 | 2025-12-23 | 2026-07-22 |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer ASP2138, Oxaliplatin, Leucovorin - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 25 | 2025-10-16 | 2026-09-02 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2025-06-23 | 2026-09-09 |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome | Phase 1 | Recruiting | Children's Oncology Group | 36 | 2025-02-04 | 2026-08-25 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors LY4066434., Cetuximab, Nab paclitaxel - Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 750 | 2024-10-21 | 2026-07-20 |
| M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) M9466, Irinotecan, Folinic acid - Advanced Solid Tumor | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2024-10-08 | 2025-12-18 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 160 | 2024-09-20 | 2026-10-07 |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. PF-07934040, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Active not recruiting | Pfizer | 64 | 2024-06-27 | 2026-10-13 |
| Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 96 | 2024-04-01 | 2024-03-15 |
| Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis Aldesleukin, Biopsy Procedure, Biospecimen Collection - Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma | Phase 1 | Active not recruiting | Mayo Clinic | 15 | 2023-11-29 | 2026-07-01 |
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane Cytarabine, Fludarabine, Leucovorin - Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2023-10-10 | 2026-06-02 |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
Showing 20 of 70. Sign in to see all of them.
Colorectal Neoplasms (19) · Pancreatic Neoplasms (15) · Colonic Neoplasms (9) · Neoplasm Metastasis (9) · Rectal Neoplasms (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Stomach Neoplasms (7) · Esophageal Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasms (5) · Leukemia, Myeloid, Acute (4) · Lung Neoplasms (4) · Myelodysplastic Syndromes (4) · Carcinoma, Pancreatic Ductal (3) · Gastrointestinal Neoplasms (3)
M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (6) · City of Hope Medical Center (3) · Jonsson Comprehensive Cancer Center (3) · Pfizer (3) · Astellas Pharma Global Development, Inc. (2) · Children's Oncology Group (2) · EMD Serono Research & Development Institute, Inc. (2) · Ludwig Institute for Cancer Research (2) · Mayo Clinic (2) · Merck Sharp & Dohme LLC (2) · NuCana plc (2) · OHSU Knight Cancer Institute (2) · Ohio State University Comprehensive Cancer Center (2) · St. Jude Children's Research Hospital (2)
United States (57) · Spain (8) · France (7) · South Korea (6) · United Kingdom (6) · Australia (5) · Canada (5) · Germany (5) · Italy (5) · Japan (4) · Puerto Rico (4) · Norway (3) · Taiwan (3) · Belgium (2) · China (2)
Marwan G Fakih (2) · Alexander Knuth, MD (1) · Alexandra M Stevens (1) · Andrew E Place, MD, PhD (1) · Anish Thomas, MD (1) · Ann Raldow (1) · Anne M Noonan, MBBChBAO, MSc (1) · Anthony Shields (1) · Aung Naing, MD (1) · Barone C., M.D. (1) · Benjamin Spieler, MD (1)
PMID 23664013, PMID 31534013, PMID 32598257, PMID 32939319, PMID 33142018, PMID 33909232, PMID 34562230, PMID 34904813, PMID 34965890, PMID 36841758, PMID 36940261, PMID 37129197, PMID 39754485, PMID 39816915, PMID 39841295, PMID 39863139, PMID 39945382, PMID 40739424, PMID 41133726, PMID 41449151, PMID 41692013
P30CA033572 (3), 2009 (2), 2015 (2), 2016 (2), 2023 (2), P30CA015083 (2), UM1CA186689 (2), UM1CA228823 (2), 2017 (1), 2018 (1), 2025 (1), P30CA016359 (1), P30CA016672 (1), P30CA022453 (1), P30CA069533 (1)